Exploring the critical role of E2F-1 transcription factor in breast cancer progression and its potential as a diagnostic and prognostic biomarker
E2F-1 controls the expression of genes required for G1 to S phase transition, including cyclins, CDKs, and DNA replication enzymes 5 . The protein interacts with retinoblastoma protein (pRb) in a phosphorylation-dependent manner 6 .
E2F-1 overexpression has been documented in various breast cancer subtypes and correlates with specific clinical parameters . Its expression pattern provides valuable prognostic information and potential therapeutic targets .
| Breast Cancer Subtype | E2F-1 Expression | Correlation with Prognosis |
|---|---|---|
| Luminal A | Moderate | Variable |
| Luminal B | High | Poor |
| HER2-positive | Very High | Poor |
| Triple Negative | High | Poor |
E2F-1 expression analysis shows promise as a diagnostic tool in breast cancer management . Its detection methods include:
E2F-1 expression levels correlate with clinical outcomes and treatment response . Key prognostic associations include:
HR: 1.45
HR: 1.67
Improved
The central role of E2F-1 in cell cycle regulation makes it an attractive therapeutic target . Several approaches are being explored to modulate E2F-1 activity in breast cancer treatment .